Rate
1 votes
Info
11.08.2011 (286 Days Ago)
| Title | NVLX | ||
| Country | United States |
Fans
Description
Nuvilex, Inc.
(OTCQB: NVLX)
New Experienced Management Completes Reorganization with Focus on Cutting Edge Areas of Biotechnology; Plan to Also Advance Existing Portfolio of 14 Patents Includes Products Entering Multi-Billion Dollar Markets
CEO of Nuvilex, Dr. Robert F. Ryan: "owning this advanced therapeutic technology, Nuvilex will become a significant player in the biotechnology arena …”
Nuvilex is a Green Company believing in “Good for You, Good for the Environment” and is expanding its natural product lines and making important strides to enter into biotechnology. Current products include Cinnergen™ for healthy glucose maintenance; Cinnechol™ to maintain healthy lipids and cardiovasculature; Talsyn™ for keloids, erythema, and scar management; NumaDerm™ cosmetic products; Citroxin™ and Oraphyte™ antimicrobial and antinematodal agents; Reme-Flu™, Legacy Biotechnologies’ flu combating regimen; and Virgin® and Infinitink®, heavy-metal-free tattoo inks.
Following a recently completed reorganization, Nuvilex has set an agenda to acquire the most cutting-edge growth areas in the biotechnology arena. A planned acquisition involves therapeutic treatment potential for pancreatic cancer, an aggressive, invasive disease responsible for 37,000 annual deaths in the U.S. alone. This acquisition will enable Nuvilex to provide encapsulated, living cells engineered to target tumors in patients with minimal collateral tissue damage.
Current Products
Cinnergen
Cinnergen is a liquid whole food nutritional supplement that enhances your diet by providing the vital nutrients many of which are deficient or may be missing altogether from a normal diet your body needs to properlymetabolize sugar and use it as energy. The whole food concentrates in Cinnergen include amino acids, vitamins, minerals, trace minerals, enzymes, bioflavonoids, antioxidants and several phyto chemicals, all of which are beneficial to the body. Better still, Cinnergen delivers these nutrients in proper proportion for the body to use them immediately.
Cinnergen delivers concentrated nutrition to help the body efficiently and effectively metabolize sugar. One of the main reasons blood sugar imbalances occur is because the typical diet is not only high in sugar but also deficient in several of the vital nutrients the body needs to properly process sugar and turn it into energy. If these nutrients are not provided by the foods we eat, our bodies are forced to leach them from elsewhere in the system. As a whole food complex, Cinnergen provides several key ingredients that have been found through emerging science and years of research to improve digestion and utilization of sugar. As the body becomes more efficient with glucose metabolism, overall health is improved.
It is estimated that 47 million US residents have metabolic syndrome1 (also referred to as insulin resistance). Insulin resistance is a complex process whereby the body loses its ability to use the insulin it secretes to metabolize blood sugar inside the cells for energy. Consequently, as this person becomes tired or fatigued, he or she feels the need to eat even more sugar. As this process escalates, sensitivity is further reduced. Blood sugar continues to rise, as does insulin production. These two factors contribute to a wide array of health problems often way before and independent of the onset of a more serious blood sugar problem diagnosed by a physician.
Reme-Flu
Reme-Flu is a unique two part homeopathic medicine for preventing and treating symptoms of flu including fever, aches and pains, chills, runny nose and cough. Reme-Flu is comprised of two individual steps. Step 1 is a homeopathic formula focused on treating general flu symptoms and is delivered in a single sub-lingual tablet. The formula for Step 2 focuses more on flu symptoms commonly associated with the respiratory system and is delivered in a sub-lingual liquid vehicle. Because respiratory symptoms can be so pronounced with the flu, the Step 2 formula is combined with unique Syn-X9 Formulation. Syn-X9 is a special blend of homeopathic compound that enhances cellular absorption of the active ingredients. It can also help cells better expel noxious materials from the cell thereby expediting the healing process.
Reme-Flu is meant to be taken at the onset of symptoms three times a day, for a four day treatment course. For best results, the entire course of treatment should be completed according to directions. One dose should be taken in the morning, afternoon and prior to bed each day. The doses should be taken at approximately the same time each of the four days. A complete dose is comprised of taking one tablet and allowing it to dissolve completely under the tongue, followed by 20 drops of liquid to be held in the mouth for approximately 30 seconds, and then swallow.
Cinnechol™
Cinnechol™ – is the all-natural nutritional supplement designed to work in harmony with your body to help normalize cholesterol and triglyceride levels — without harmful side effects. Cinnechol’s all-natural ingredients work together to improve circulation and decrease inflammation which are vital components of heart and circulatory health.
Talsyn
Talsyn is for the serious management of Keloids, Hypertrophic Scars, Erythema, and Surgical Incisions. Talsyn has been clinically proven to facilitate healing and improve the appearance, redness, and tensile strength of scars. Talsyn is used and endorsed by leading plastic and reconstructive surgeons.
Talsyn-CI Scar Cream is a Lipid-Peptide compound with a pleasant fragrance. Talsyn-CI is a synergistic blend of several innovative fatty acids, unique peptides, and complimentary botanical extracts. It is safe to use with all clothing and will not damage or stain fabric.
This proprietary patent pending blend of ingredients has the unique ability of penetrating deep into the layers of the skin where wound healing occurs. Synthesis of new collagen which is vital to the process of wound healing is stimulated. Other ingredients deliver anti-inflammatory and wound healing properties. Numerous nutrients in Talsyn’s botanicals help create an optimal environment for the skin to repair itself in the fastest, most efficient organized configuration; thus allowing the scar to most closely resemble its original skin integrity. Results can be seen in as little as two to four weeks. Continue use as recommended by the attending physician.
Infinitink®
Infinitink® is a high quality tattoo ink that is engineered to be permanent and safe and is far easier to remove from the skin than traditional tattoo inks. Infinitink is applied to the skin in the same way as any other tattoo. It also stays in the skin for as long as you wish. If, however, you choose to have your Infinitink tattoo removed, it will come out of the skin in fewer treatments than tattoos made with traditional inks.
Citroxin™ - A patented blockbuster product, Citroxin™, looks like it will be offered later this year which could emerge as a major sales driver. Citroxin™ is a “green” surface cleaner and sterilizer that rivals chemical cleaners. We believe Nuvilex is in the 8th inning of the product submission and approval with the EPA. Once approved, Nuvilex could elect to private label the product or sell it directly to consumer, hospitals and other businesses seeking an eco-friendly alternative to current, toxic, chemical-based products. The current market opportunity is likely $10 billion annually.
Oraphyte™ - Much like Citroxin™, Oraphyte™ is designed as an eco-friendly alternative to chemical-based products, but in this case Oraphyte™ is an all-natural nematocide. The Oraphyte™ formula is a non-toxic; biodegradable proprietary combination of organic materials is highly effective in combating nematodes harmful to grass and other plants. There is great demand for such a solution for lawn and crop protection and it has the potential ability to replace methyl bromide and other extremely hazardous chemicals presently being used in the US and abroad.
Pancreatic Cancer Treatment Technology – This acquisition will enable Nuvilex to provide encapsulated, living cells engineered to target tumors in patients with minimal collateral tissue damage. In completed clinical studies on pancreatic cancers, this treatment protocol has been shown to double life expectancy over present conventional pancreatic cancer therapy. We anticipate this treatment technology to receive much more attention once the acquisition is officially completed, and could provide a nice bump to NVLX stock at that time.
· Successful Reorganization: New management additions of CEO Dr. Robert Ryan and COO Dr. Gerald Crabtree bring contacts and knowledge that are critical to product development, redevelopment, and acquisitions. Early on, they formed a new marketing & sales department, restructured pricing to enhance gross profit margins, and made plans to release new packaging / sizes for Cinnergen. It is noted that Dr. Ryan purchased 5 million shares of restricted stock in Nuvilex at a premium when he joined the Company.
· Patented Blockbuster “Green” Cleaner product Citroxin™ - This innovative eco-friendly, antimicrobial, sterilizer and cleanser offers huge direct and private label sales potential through a market opportunity that is about $10 billion a year. Nuvilex is in the final stages of approval with the EPA to market the product and hopes to receive this approval in the second half of 2011.
· Oraphyte™ - All Natural Formula to Protect Lawns and Crops – Here is yet another product that would enter a billion dollar industry. This non-toxic, biodegradable proprietary combination of organic materials is highly effective in combating bacteria that is harmful to grass and plant growth. It has the potential to replace methyl bromide and other extremely hazardous chemicals presently being used.
· Growth of Existing Line of Nutraceutical and Cosmetic Products – Nuvilex owns a product designed to aid diabetics or pre-diabetic individuals, a product that maintains normal cholesterol levels / normal cardiovascular functions, a product to prevent and treat symptoms of flu, and more. It also owns a product known to heal scars and one that is a tattoo ink engineered to be permanent yet is far easier to remove if desired. All these products may be retained and used to drive growth, or can be sold off to raise cash to focus on businesses with even more upside growth.
· Anti-Cancer Agent Alternia™ - Initial studies, carried out at a prestigious research center in Georgia, suggested Alternia™ had potential to cause alterations in cell division and initiate apoptosis in cancer cells, a series of events typically leading to cell death. Continued successful development of Alternia™ should raise the valuation and profile for Nuvilex.
· Goldman Small Cap Research Targets .50 – Analyst Rob Goldman’s original report issued just a few weeks ago on May 10 stated that NVLX is “valued for its current portfolio only, so investors get the rest of the Company for free” and “does not reflect the expected launch of new products or the value of the pre-clinical development portfolio.” The report rates Nuvilex a Speculative Buy adding “we believe that the shares could reach $0.50 by year end.” A more recent update issued on May 19 added that “underlying value increasing yet again with latest news.”
Dr. Robert F. Ryan, President and CEO:
Dr. Robert F. Ryan was named President and Chief Executive Officer. Dr. Ryan has broad scientific experience in biochemistry, cell and molecular biology, human genetics, novel therapies, and basic and clinical cancer research, having received his Masters in Biochemistry, Cell and Molecular Biology at The Medical College of Georgia, studying sickle cell anemia. He received his Ph.D. in Molecular Genetics at Thomas Jefferson University characterizing DNA and RNA binding properties of zinc finger proteins. Through his extensive training, his experiences extend across the fields of aging, hemoglobinopathies, gene expression, human diseases, DNA, RNA, proteins and their interactions, stem cell research and applications, oncology, clinical protocols and therapies.
Professionally, Dr. Ryan has become a pioneer in the field of emerging biotechnology, specializing in assisting small companies with insight and bringing products to market through the rigorous FDA approval process. Since 2002, Dr. Ryan served as the Chief Executive Officer of RFR Consulting where he focused on helping businesses in the biotech industry through providing information, grant writing, business management, scientific guidance, FDA regulatory advice, advising investors, and investment acquisition opportunities. With 25 years experience including excellent training at the Wistar Institute, NIH, and NCI, he has participated in basic and clinical investigations and has published and edited research articles in several peer-reviewed journals.
Dr. Gerald W. Crabtree, COO:
Dr. Crabtree was recently named the Chief Operating Officer. Even in such a short period as a few weeks, he has provided a significant benefit and impact for Nuvilex, clearly matching not only the commitment to repositioning Nuvilex into the biotechnology area, but also adds to the strength of our existing products and pipeline. Dr. Ryan has worked with Dr. Crabtree and looks forward to working with him to move Nuvilex forward. He has extensive experience in the areas of natural and synthetic drug and device research and development, having worked in both academia and small and large company environments. His business and financial acumen together with his research and development background combine to make him an invaluable addition to Nuvilex.
Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles, and served as project manager for development of major oncologic agents. He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society. Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.
Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals. He is a National Cancer Institute of Canada Research Fellow. In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University. He has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation. Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions, and contracts and business plans.
Patricia Gruden, Chairman of the Board of Directors and CFO:
Ms. Patricia Gruden has made a substantial impact in many companies over the years. It was in 1995 that she became cofounder of the company that has since become Nuvilex. The original company was initiated to develop a software program through accurately tracking produce from the field to the table, including the challenges of shipping, temperature variation and maintenance, and everything else concerning the distribution of produce worldwide. In addition, the company developed an ozone cleaning system to kill bacteria on produce without leaving harmful residue on the product and without harming the environment. The company and its footprint expanded, eventually giving rise to the start of the publicly traded Nuvilex, Inc. company’s roots in 2001.
Ms. Gruden has carried out almost every job in the company over the years including developer, shipper, President, CEO, Chairman of the Board, CFO and many others. As a result, she has been intricately aware of all aspects of the company and its products throughout its history. After a short semi-retirement in 2009-10, she returned with renewed vigor and has since put in extensive effort and funding into returning the business to its former capabilities. Although her history and training has been focused in management and sales, she clearly has made substantial advances for Nuvilex.
Her training has not only included the real world experiences of running more than one company, but was well founded in her attainment of her B.S. degree in Business at the University of Oklahoma. From there, things have never been the same, propelling her to embrace every business opportunity with excitement, clarity and focus. Through the years, Patricia has had a long history of owning her own businesses, and doing so successfully, with her strengths in working with people, marketing and management. As part of her contribution and success at Nuvilex, she is President of some of the subsidiaries including Cinnergen, Inc. where she ensures organization, marketing, cash flow, and good management. Currently, Ms. Patricia Gruden is the Chairman of the Board of Directors and CFO for Nuvilex, guaranteeing a good dose of knowledge and success for the company through efficient and thoughtful oversight of the entire company and good fiscal management of our assets.
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
mmolinarofc@aol.com
7702 East Doubletree Ranch Road
Suite 300
Scottsdale, AZ 85258
Phone: (480) 348-8050
email: info@nuvilex.com
Photos
NVLX
Comments
Order by:
Per page:
- There are no comments yet
|
|